Invivyd Inc. (IVVD) Insider Trading

Last 12 months

Insiders bought $125k and sold $531k on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$406k

1 buy · 10 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

1 / 5

executives and directors

Last open-market buy

Nov 2025

Nov 19, 2025

Get an email when IVVD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 17 – 18	Timothy Edward Lee Chief Commercial Officer	Sold10b5-1 plan 2 parts	40,780	$0.77 average	$32k	19%	Form 4
Aug 17 – 18	Julie Green Chief Human Resources Officer	Sold10b5-1 plan 2 parts	40,780	$0.77 average	$32k	19%	Form 4
Aug 17 – 18	William E. Duke Chief Financial Officer	Sold10b5-1 plan 2 parts	40,780	$0.77 average	$32k	19%	Form 4
Aug 17 – 18	Jill Andersen Chief Legal Officer, Secretary	Sold10b5-1 plan 2 parts	67,962	$0.77 average	$53k	19%	Form 4
Aug 17 – 18	Robert D. Allen III Chief Scientific Officer	Sold10b5-1 plan 2 parts	37,722	$0.77 average	$29k	17%	Form 4
Feb 17 – 18	Robert D. Allen III Chief Scientific Officer	Sold10b5-1 plan 2 parts	37,581	$1.56 average	$59k	25%	Form 4
Feb 17 – 18	Julie Green Chief Human Resources Officer	Sold10b5-1 plan 2 parts	40,627	$1.56 average	$63k	27%	Form 4
Feb 17 – 18	William E. Duke Chief Financial Officer	Sold10b5-1 plan 2 parts	40,627	$1.56 average	$63k	27%	Form 4
Feb 17 – 18	Timothy Edward Lee Chief Commercial Officer	Sold10b5-1 plan 2 parts	40,627	$1.56 average	$63k	26%	Form 4
Feb 17 – 18	Jill Andersen Chief Legal Officer, Secretary	Sold10b5-1 plan 2 parts	67,710	$1.56 average	$106k	27%	Form 4
Nov 19, 2025	Kevin F McLaughlin Director	Bought	50,000	$2.50	$125k	New	Form 4
Aug 18, 2025 – Aug 19, 2025	Timothy Edward Lee Chief Commercial Officer	Sold10b5-1 plan 2 parts	49,656	$0.60 average	$30k	46%	Form 4
Aug 18, 2025 – Aug 19, 2025	William E. Duke Chief Financial Officer	Sold10b5-1 plan 2 parts	49,656	$0.60 average	$30k	50%	Form 4
Aug 18, 2025 – Aug 19, 2025	Julie Green Chief Human Resources Officer	Sold10b5-1 plan 2 parts	49,656	$0.60 average	$30k	50%	Form 4
Aug 18, 2025 – Aug 19, 2025	Jill Andersen Chief Legal Officer, Secretary	Sold10b5-1 plan 2 parts	82,754	$0.60 average	$50k	49%	Form 4
Aug 18, 2025 – Aug 19, 2025	Robert D. Allen III Chief Scientific Officer	Sold10b5-1 plan 2 parts	45,932	$0.60 average	$28k	46%	Form 4
Dec 27, 2024 – Dec 31, 2024	Terrance McGuire Director	SoldNo plan 3 parts	273,763	$0.48 average	$132k	8.2%	Form 4
Dec 20, 2024 – Dec 26, 2024	Terrance McGuire Director	SoldNo plan 4 parts	347,559	$0.47 average	$164k	9.4%	Form 4
Dec 17, 2024 – Dec 19, 2024	Terrance McGuire Director	SoldNo plan 3 parts	324,241	$0.45 average	$147k	8.1%	Form 4
Dec 12, 2024 – Dec 16, 2024	Terrance McGuire Director	SoldNo plan 2 parts	190,359	$0.54 average	$103k	4.5%	Form 4
Dec 9, 2024 – Dec 11, 2024	Terrance McGuire Director	SoldNo plan 3 parts	485,400	$0.60 average	$289k	10%	Form 4

Aug 17 – 1810b5-1 plan
Timothy Edward Lee
Chief Commercial Officer · sold 40,780 at avg $0.77
$32k
19% of stake
Aug 17 – 1810b5-1 plan
Julie Green
Chief Human Resources Officer · sold 40,780 at avg $0.77
$32k
19% of stake
Aug 17 – 1810b5-1 plan
William E. Duke
Chief Financial Officer · sold 40,780 at avg $0.77
$32k
19% of stake
Aug 17 – 1810b5-1 plan
Jill Andersen
Chief Legal Officer, Secretary · sold 67,962 at avg $0.77
$53k
19% of stake
Aug 17 – 1810b5-1 plan
Robert D. Allen III
Chief Scientific Officer · sold 37,722 at avg $0.77
$29k
17% of stake
Feb 17 – 1810b5-1 plan
Robert D. Allen III
Chief Scientific Officer · sold 37,581 at avg $1.56
$59k
25% of stake
Feb 17 – 1810b5-1 plan
Julie Green
Chief Human Resources Officer · sold 40,627 at avg $1.56
$63k
27% of stake
Feb 17 – 1810b5-1 plan
William E. Duke
Chief Financial Officer · sold 40,627 at avg $1.56
$63k
27% of stake
Feb 17 – 1810b5-1 plan
Timothy Edward Lee
Chief Commercial Officer · sold 40,627 at avg $1.56
$63k
26% of stake
Feb 17 – 1810b5-1 plan
Jill Andersen
Chief Legal Officer, Secretary · sold 67,710 at avg $1.56
$106k
27% of stake
Nov 19, 2025
Kevin F McLaughlin
Director · bought 50,000 at $2.50
$125k
New position
Aug 18, 2025 – Aug 19, 202510b5-1 plan
Timothy Edward Lee
Chief Commercial Officer · sold 49,656 at avg $0.60
$30k
46% of stake
Aug 18, 2025 – Aug 19, 202510b5-1 plan
William E. Duke
Chief Financial Officer · sold 49,656 at avg $0.60
$30k
50% of stake
Aug 18, 2025 – Aug 19, 202510b5-1 plan
Julie Green
Chief Human Resources Officer · sold 49,656 at avg $0.60
$30k
50% of stake
Aug 18, 2025 – Aug 19, 202510b5-1 plan
Jill Andersen
Chief Legal Officer, Secretary · sold 82,754 at avg $0.60
$50k
49% of stake
Aug 18, 2025 – Aug 19, 202510b5-1 plan
Robert D. Allen III
Chief Scientific Officer · sold 45,932 at avg $0.60
$28k
46% of stake
Dec 27, 2024 – Dec 31, 2024No plan
Terrance McGuire
Director · sold 273,763 at avg $0.48
$132k
8.2% of stake
Dec 20, 2024 – Dec 26, 2024No plan
Terrance McGuire
Director · sold 347,559 at avg $0.47
$164k
9.4% of stake
Dec 17, 2024 – Dec 19, 2024No plan
Terrance McGuire
Director · sold 324,241 at avg $0.45
$147k
8.1% of stake
Dec 12, 2024 – Dec 16, 2024No plan
Terrance McGuire
Director · sold 190,359 at avg $0.54
$103k
4.5% of stake
Dec 9, 2024 – Dec 11, 2024No plan
Terrance McGuire
Director · sold 485,400 at avg $0.60
$289k
10% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IVVD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

CSBRChampions Oncology, Inc.

FENCFennec Pharmaceuticals Inc.

CHRSCoherus Biosciences Inc.

RXRXRecursion Pharmaceuticals, Inc.

STROSutro Biopharma, Inc.

DTILPrecision Biosciences Inc.

CGENCompugen Ltd.

EDITEditas Medicine Inc.

Spot a number that looks wrong? Check it in IVVD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IVVD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.